Results for the First Quarter 2022

All-time high sales for a quarter ending at MNOK 116.1 (MNOK 102.6), an increase of 13.2%. Sales growth is driven by the USA with a currency-neutral increase of 34.2%. Currency neutral sales of own products…

Read more

Results for the Third Quarter 2021

Sales revenues for the quarter ended at MNOK 102.1 (MNOK 83.4), an increase of 22.5%. Sales as of September ended at MNOK 309.2 (MNOK 268.9) a 15.0% increase. Sales in the USA increased by 11.9…

Read more

Results for the First Quarter 2021

Sales for the quarter ended at MNOK 102.6 (MNOK 103.1), on par with the sales record set in Q1 last year. Currency neutral, sales increased by 1.5%. Second best quarter ever for operating result (EBIT)…

Read more

Annual Report 2019

We have now achieved a market penetration of 23% in USA, measured as the share of bypass procedures done with Medistim’s devices. Our position in Asia and Europe is also strengthened, through increased sales and…

Read more

The REQUEST study is now published

The REQUEST study is a multicenter, prospective study among 7 international centers performing coronary artery bypass grafting procedures.  The primary endpoint was any change in the planned surgical procedure. Major secondary endpoints consisted of the…

Read more

MiraQ approved for sale in Canada

MiraQ™ is Medistim's newest generation of products for quality assurance within  vascular and cardiac surgery. The system is based on ultrasound, and combines quantitative blood flow volume through transit time flow measurement (TTFM)  with morphological…

Read more